Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers

Marked interindividual variability in voriconazole exposure persists among CYP2C19 NMs and IMs. Integrating therapeutic drug monitoring (TDM) with genetic and clinical factors may optimize dosing and reduce hepatotoxicity risk. Larger multicentre studies are still needed.